NPM1 and acute myeloid leukemia: Although about 10% of patients bearing a NPM1mut AML at diagnosis relapse with a NPM1WT AML, the detection of mutant NPM1 using sensitive molecular techniques is a sensitive assay to detect the persistence of MRD after induction and consolidation therapy and to predict the risk of recurrence [67].